Aardvark Therapeutics (AARD) Other financing activities (2024 - 2026)
Aardvark Therapeutics (AARD) posted Other financing activities of -$91.1 million for Q4 2025, down 200.12% sequentially from $91.0 million in Q2 2025, and down 8994.04% YoY from $1.0 million in Q4 2024.
Aardvark Therapeutics (AARD) Other financing activities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Other financing activities for 2 years, with the latest figure at -$91.1 million in Q4 2025.
- Quarterly Other financing activities fell 8994.04% year-over-year to -$91.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$110000.0 (down 108.44% YoY) and the FY2024 annual result came in at $1.2 million, changed N/A from the prior year.
- Other financing activities eased to -$91.1 million in Q4 2025 per AARD's latest filing, from $91.0 million in the prior quarter.
- Over five years, Other financing activities peaked at $91.0 million in Q2 2025 and troughed at -$91.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -91.08 Mn |
| Dec 31, 2025 | -91.08 Mn |
| Jun 30, 2025 | 90.97 Mn |
| Jun 30, 2025 | 90.97 Mn |
| Mar 31, 2025 | 110,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |